HC Wainwright & Co. Maintains Buy on Immunic, Raises Price Target to $22
Benzinga Newsdesk 6 months ago
NewsPrice TargetStock SplitAnalyst Ratings
HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and raises the price target from $5 to $22.
HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and raises the price target from $5 to $22.